Syneron Medical Ltd. (ELOS) announced that is has signed a definitive agreement to acquire substantially all the assets of TransPharma Medical Ltd., a specialty pharmaceutical company focused on the development and commercialization of drug-products utilizing an active transdermal drug delivery technology.
As per terms of the agreement, Syneron will acquire substantially all the assets of TransPharma, including its patent portfolio, for approximately $3.6 million in cash. The acquisition is subject to customary closing conditions.
For comments and feedback: editorial@rttnews.com